obecabtagene autoleucel

AXP000019.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
CD19
Originator
Autolus Therapeutics
Sponsor
Autolus Therapeutics

Names

NameTypeSource
obecabtagene autoleucelpreferred name, INNcurator, ncit
Aucatzylbrandncit
AUTO1codencit
obe-celsynonymncit

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
lentivirus
Replication
non replicating
Modifications
replication-incompetent lentiviral vector containing the CD19 CAR transgene; murine anti-CD19 scFv with 4-1BB costimulatory and CD3 zeta signalling domains
Transgenes
anti-CD19 chimeric antigen receptor
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C172746
Wikidata
Q131314725
FDA UNII
760HJB0YRD

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2024-11-08approvedAucatzylAdults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemiasource
EMAEU2025-07-17conditionalAucatzylAdults aged 26 and over with relapsed or refractory B-cell precursor acute lymphoblastic leukaemiasource

Clinical trials (8)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07400029A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 22026-02-032029-0240Acute Lymphoblastic Leukemia
NCT07053800Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)RecruitingPhase 22026-01-162028-0835Lupus Nephritis
NCT07053059Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)RecruitingPhase 22025-08-262028-05-3130Acute Lymphocytic Leukemia (ALL)
NCT07139743Obe-cel in Refractory Progressive Forms of Multiple SclerosisRecruitingPhase 12025-08-042029-08-1524Progressive Multiple Sclerosis
NCT06333483Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus ErythematosusActive not recruitingPhase 12024-02-022027-0916Systemic Lupus Erythematosus
NCT06173518A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)RecruitingPhase 12023-11-162027-1130Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
NCT04404660A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)Active not recruitingPhase 1/22020-06-032029-06-30153Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
NCT06799221Expanded Access Program for OOS Obe-celAvailableB Cell ALL; Lymphoblastic Leukemia, Acute, Adult

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41504229Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Haematologica2026cited by trial NCT04404660
PMID 42241689CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.Cancer research communications2026name in title: obecabtagene autoleucel
PMID 42469475Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Leukemia2026name in title: obecabtagene autoleucel
PMID 41671463Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN2025cited by trial NCT06173518
PMID 39602653Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.The New England journal of medicine2024cited by trial NCT04404660
Unconfirmed matches (2)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 34464155Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2021name in abstract: AUTO1
PMID 12679622Immunologic effects of allogeneic versus autologous blood transfusion in patients undergoing radical oesophagectomy.European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes2003name in abstract: AUTO1

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41826187[Obecabtagene autoleucel (Obe-cel) in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia].Bulletin du cancer2026name in title: obecabtagene autoleucel
PMID 42373851False-positive HIV-1 RNA detection following obecabtagene autoleucel.Bone marrow transplantation2026name in title: obecabtagene autoleucel
PMID 42381271Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database.Japanese journal of clinical oncology2026name in abstract: obecabtagene autoleucel
PMID 42572849Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety.The Annals of pharmacotherapy2026name in title: obecabtagene autoleucel
PMID 42609184Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".Haematologica2026name in title: obecabtagene autoleucel
PMID 39791458Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.Leukemia & lymphoma2025name in abstract: obecabtagene autoleucel
PMID 39888581Obecabtagene Autoleucel: First Approval.Molecular diagnosis & therapy2025name in title: obecabtagene autoleucel
PMID 39928344Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia.JAMA2025name in title: obecabtagene autoleucel
PMID 39930262Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL.Nature reviews. Clinical oncology2025name in title: obecabtagene autoleucel
PMID 39954668Always more immunotherapy in the management of B-lineage acute lymphoblastic leukemia.Med (New York, N.Y.)2025name in abstract: obecabtagene autoleucel
PMID 39954962Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells.Transplantation and cellular therapy2025name in abstract: obecabtagene autoleucel
PMID 40550480Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion?Expert review of hematology2025name in title: obecabtagene autoleucel
PMID 40550595An interview with Dr. Jean A. Yared on his experience as an investigator for obecabtagene autoleucel - by Reegan Burnell-Clarke (Commissioning Editor).Expert review of hematology2025name in title: obecabtagene autoleucel
PMID 41201546Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy.Current hematologic malignancy reports2025name in abstract: obecabtagene autoleucel
PMID 39559248Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.Cancer management and research2024name in abstract: obecabtagene autoleucel
PMID 39762192In brief: Obecabtagene autoleucel (Aucatzyl) - another CAR-T cell immunotherapy for ALL.The Medical letter on drugs and therapeutics2024name in title: obecabtagene autoleucel
PMID 36945773Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.Molecular therapy : the journal of the American Society of Gene Therapy2023name in abstract: obe-cel
PMID 37709295AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival.Journal for immunotherapy of cancer2023name in title: AUTO1
Unconfirmed matches (5)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 42665916Real-world clinical impact of implementing and updating a deep learning-based automatic contouring system in rectal cancer radiotherapy.Journal of applied clinical medical physics2026name in abstract: AUTO1
PMID 37647647CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.Blood2024name in abstract: AUTO1
PMID 39341137Protective role of ghrelin against 6PPD-quinone-induced neurotoxicity in zebrafish larvae (Danio rerio) via the GHSR pathway.Ecotoxicology and environmental safety2024name in abstract: AUTO1
PMID 21780236Fully automatic geometry planning for cardiac MR imaging and reproducibility of functional cardiac parameters.Journal of magnetic resonance imaging : JMRI2011name in abstract: AUTO1
PMID 8557329A patient-derived cytotoxic T-lymphocyte clone and two peptide-dependent monoclonal antibodies recognize HLA-B27-peptide complexes with low stringency for peptide sequences.Infection and immunity1996name in abstract: AUTO1

Notes

Fast-off-rate anti-CD19 (CAT19) 4-1BB CAR from UCL (Pule lab), developed by UCL spin-out Autolus.

How to cite

obecabtagene autoleucel (AXP000019.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000019.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.